Cargando…
Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
This study aimed to evaluate whether the therapeutic switch from a formulation of Bimatoprost 0.1 mg/mL with benzalkonium chloride (BAK) or Bimatoprost 0.3 mg/mL preservative-free to a formulation of Bimatoprost 0.1 mg/mL preservative-free could improve eye surface conditions in patients with glauco...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224644/ https://www.ncbi.nlm.nih.gov/pubmed/35743588 http://dx.doi.org/10.3390/jcm11123518 |
_version_ | 1784733418899111936 |
---|---|
author | Filippelli, Mariaelena Campagna, Giuseppe Ciampa, Nicola Fioretto, Gaetano Giannini, Roberta Marino, Pier Franco dell’Omo, Roberto Costagliola, Ciro |
author_facet | Filippelli, Mariaelena Campagna, Giuseppe Ciampa, Nicola Fioretto, Gaetano Giannini, Roberta Marino, Pier Franco dell’Omo, Roberto Costagliola, Ciro |
author_sort | Filippelli, Mariaelena |
collection | PubMed |
description | This study aimed to evaluate whether the therapeutic switch from a formulation of Bimatoprost 0.1 mg/mL with benzalkonium chloride (BAK) or Bimatoprost 0.3 mg/mL preservative-free to a formulation of Bimatoprost 0.1 mg/mL preservative-free could improve eye surface conditions in patients with glaucoma; intraocular pressure (IOP) was also evaluated. All patients meeting the inclusion criteria were eligible for the therapeutic switch to Bimatoprost 0.1 mg/mL preservative-free. At each check visit, enrolled patients underwent a break-up time (BUT) test, an ocular surface disease index (OSDI) test, and a three-point tonometric curve. A total of 40 patients were enrolled (23 were in therapy with Bimatoprost 0.1 mg/mL with BAK and 17 with Bimatoprost 0.3 mg/mL preservative-free). Significant differences of OSDI and BUT between Bimatoprost 0.1 mg/mL with BAK at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 and p = 0.0003, respectively) were recorded. Similarly, significant differences of OSDI and BUT between Bimatoprost 0.3 mg/mL preservative-free at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 for both) were found. Bimatoprost 0.1 mg/mL preservative-free has a better tolerability profile associated with non-therapeutical inferiority in the control of IOP compared to the other Bimatoprost formulations. |
format | Online Article Text |
id | pubmed-9224644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92246442022-06-24 Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma Filippelli, Mariaelena Campagna, Giuseppe Ciampa, Nicola Fioretto, Gaetano Giannini, Roberta Marino, Pier Franco dell’Omo, Roberto Costagliola, Ciro J Clin Med Article This study aimed to evaluate whether the therapeutic switch from a formulation of Bimatoprost 0.1 mg/mL with benzalkonium chloride (BAK) or Bimatoprost 0.3 mg/mL preservative-free to a formulation of Bimatoprost 0.1 mg/mL preservative-free could improve eye surface conditions in patients with glaucoma; intraocular pressure (IOP) was also evaluated. All patients meeting the inclusion criteria were eligible for the therapeutic switch to Bimatoprost 0.1 mg/mL preservative-free. At each check visit, enrolled patients underwent a break-up time (BUT) test, an ocular surface disease index (OSDI) test, and a three-point tonometric curve. A total of 40 patients were enrolled (23 were in therapy with Bimatoprost 0.1 mg/mL with BAK and 17 with Bimatoprost 0.3 mg/mL preservative-free). Significant differences of OSDI and BUT between Bimatoprost 0.1 mg/mL with BAK at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 and p = 0.0003, respectively) were recorded. Similarly, significant differences of OSDI and BUT between Bimatoprost 0.3 mg/mL preservative-free at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 for both) were found. Bimatoprost 0.1 mg/mL preservative-free has a better tolerability profile associated with non-therapeutical inferiority in the control of IOP compared to the other Bimatoprost formulations. MDPI 2022-06-19 /pmc/articles/PMC9224644/ /pubmed/35743588 http://dx.doi.org/10.3390/jcm11123518 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Filippelli, Mariaelena Campagna, Giuseppe Ciampa, Nicola Fioretto, Gaetano Giannini, Roberta Marino, Pier Franco dell’Omo, Roberto Costagliola, Ciro Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma |
title | Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma |
title_full | Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma |
title_fullStr | Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma |
title_full_unstemmed | Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma |
title_short | Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma |
title_sort | ocular tolerability of bimatoprost 0.1 mg/ml preservative-free versus bimatoprost 0.1 mg/ml with benzalkonium chloride or bimatoprost 0.3 mg/ml preservative-free in patients with primary open-angle glaucoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224644/ https://www.ncbi.nlm.nih.gov/pubmed/35743588 http://dx.doi.org/10.3390/jcm11123518 |
work_keys_str_mv | AT filippellimariaelena oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma AT campagnagiuseppe oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma AT ciampanicola oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma AT fiorettogaetano oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma AT gianniniroberta oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma AT marinopierfranco oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma AT dellomoroberto oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma AT costagliolaciro oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma |